NBRV - Nabriva Therapeutics plc
| Previous Close | 1.8300 |
| Open | 1.8500 |
| Bid | 0.0000 x 4000 |
| Ask | 2.1200 x 2900 |
| Day's Range | 1.8300 - 1.8900 |
| 52 Week Range | 1.1200 - 3.2700 |
| Volume | 644,951 |
| Avg. Volume | 1,138,458 |
| Market Cap | 148.082M |
| Beta (3Y Monthly) | 2.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2770 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.42 |
- GlobeNewswire
Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Gary Sender Chief Financial Officer and Francesco Lavino Chief Commercial Officer, will provide a company overview and business update at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 4:30 p.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA™ (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
- Benzinga
Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio
ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date. Nabriva has a commercial product in lefamulin IV/oral, which was approved by the FDA in August for treating community-acquired bacterial pneumonia, or CABP. The mode of action is through binding to the peptidyl transferase center present in the ribosome of the bacteria, interfering with the interaction of protein production at two key sites — the A site and P site — that inhibit protein production and in turn the growth of bacteria.
- GlobeNewswire
Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship
S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community.
- GlobeNewswire
Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
-More than 200 hospital formulary reviews of XENLETA™ scheduled before the end of the year- -Approximately 50% of all covered lives have outpatient formulary access to XENLETA-.
- GlobeNewswire
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 90,000 ordinary shares of Nabriva Therapeutics as inducements to 3 newly-hired employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The stock options were granted effective October 31, 2019 with an exercise price of $1.93 per share, which is equal to the closing price of Nabriva Therapeutics’s ordinary shares on the date of grant.
- GlobeNewswire
Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, November 12, 2019. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com.
- GlobeNewswire
Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it will present data on the pooled results from completed Phase 3 trials of XENLETA™ (lefamulin) at the CHEST Annual Meeting 2019, to be held October 19-23 in New Orleans. XENLETA is a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of community-acquired bacterial pneumonia (CABP) in adults and is now commercially available in the United States. “The clinical community desperately needs new classes of antibiotics with different mechanisms of action that have targeted, potent antimicrobial activity and improved safety and tolerability over existing therapies,” said Jennifer Schranz, M.D., Chief Medical Officer of Nabriva Therapeutics.
- TipRanks
3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020
In any industry, there are always deals that are too good to be true and unfortunately, they usually are. The best thing to do before any kind of investment is to educate yourself before you make any hasty decisions. Being extra cautious could be an excellent idea.When it comes to the stock market though, “playing it safe” doesn’t always pay off and putting your money on a seemingly ‘sure bet’ that most big players are investing in, might not get you the results you are actually looking for.When you take a deeper look, you’ll notice that there are actually incredible opportunities in “smaller” and less heard of biotech stocks that can bring you closer to the sweet payday.Using TipRanks’ Stock Screener, we’ve highlighted 3 ultra-promising biotechs that are showing upside of nearly 300% and above.Gamida Cell (GMDA) Gamida Cell is a clinical-stage biopharmaceutical company that is creating and developing cell therapies for different types of cancers. The company has its own proprietary nicotinamide-based (or NAM based) cell expansion technology which is pretty much its “trade secret." NAM-based cell expansion takes the natural state of cancer cells and modifies them so that they are no longer harmful to the body.Gamida is hoping to bank on the success of its frontrunner drug ‘omidubicel’ which is expected to be a life-saving stem cell transplant solution for patients with high-risk blood cancers and bone marrow failure disorders. Omidubicel is currently in Phase 3 of its clinical trials.4-star JMP analyst Jason N. Bulter sees the Phase 3 results for omidubicel in 1H20 “as the primary value driver for the stock” and identifies “potential for success based on positive Phase 2 results.” And that’s good enough reason for Bulter to rate the stock an Outperform along with $16 price target. If the price target is reached within 12 months, that would provide a 12-month return of nearly 261%."Our..price target is derived through an NPV analysis of omidubicel sales, for which we project U.S. sales of ~$580MM by 2027 and assign a 75% probability of approval.” the analyst explained.Overall, we can see from TipRanks that Gamida has a “Strong Buy” consensus rating. In the last three months, the stock has received 22 buy ratings and seven hold ratings. Based on these ratings, the average $175 price target on X stock translates into upside of over 10% from the current share price.Gamida stock has a resounding “yes” on Wall Street. TipRanks analytics show that out of three analysts polled in the past 3 months, all three are bullish. The price target of $17.67 shows a potential upside of about nearly 300% from where the stock is currently trading. (See Gamida stock analysis on TipRanks)Nabriva Therapeutics (NBRV) Similarly to GMDA, Nabriva Therapeutics is a company that also has 2 premiere projects in the works and has a lot of promising developments going on. Nabriva's lead drug XENLETA, which treats patients with community-acquired bacterial pneumonia (CABP), recently won FDA approval and is being distributed in the U.S. since August. Nabriva also recently acquired Zvante Therapeutics and added CONTEPO to its portfolio; an injection for the treatment of complicated urinary tract infections. In contrast to XENLETA, however, CONTEPO has yet to gain FDA approval.Northland analyst Carl Brynes is forecasting "peak global sales of XENLETA at $1B, supported by XENLETA's clinical differentiation and oral/IV dosing forms." With a market cap of only $130.58 million, the analyst sees huge upside for NBRV stock, as he reiterates an Outperform rating and $12.50 price target. (To watch Brynes' track record, click here)Wedbush analyst Robert Driscoll added, "We see XENLETA’s profile as well suited for the treatment of CABP, given its favorable safety and efficacy profile, a narrow but CABP-targeted spectrum, and flexible IV to oral/oral dosing. Importantly, two Ph 3 studies have demonstrated efficacy with a short treatment course of 5-7 days, which we note aligns with antibiotic stewardship principles. With recent favorable changes to the reimbursement landscape and a clear plan in place for lefamulin commercialization, plus clarification around second asset CONTEPO NDA resubmission timelines, we believe NBRV shares are currently undervalued."All in all, the drug maker is without question a Wall Street favorite, considering TipRanks analytics indicate NBRV as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on the stock. With a return potential of nearly 390%, the stock's consensus target price stands at $8.70. (See Nabriva stock analysis on TipRanks)PhaseBio Pharmacuticals (PHAS)Rounding out our list is PhaseBio Pharmacuticals, a clinical-stage biopharmaceutical, developing treatments for orphan diseases with cardiopulmonary indications. PhaseBio's stake in the race is PB2452; medication that the company hopes will undo the negative effects of the antiplatelet drug ticagrelor. The company also has a really good second offering in PB1046; its treatment of PAH (pulmonary arterial hypertension), which creates high blood pressure in the arteries of the lungs.The company recently announced that it completed the Phase 2a clinical trial of PB2452 on healthy elderly patients and that the results have been consistent to its former Phase 1 study with younger, healthy patients. This is good news for PHAS and shows that the company is right on track with its clinical trial advances.William Blair analyst Matt Phipps believes “the completion of the Phase 2a study continues a pattern of excellent execution from company management, and we look forward to the full data presentation at an upcoming medical conference and initiation of pivotal trials in the coming months." The analyst added that “the base case...for PB2452, which assumes a peak penetration for ticagrelor of 40% of the addressable market, results in a risk-adjusted net present value of roughly $16 per share.”With that in mind, it's not surprising why Phipps reiterated an Outperform rating on PHAS stock, while boosting his price target to $7.00 (from $5.00).How does Phipps' bullish forecast echo against the word of the Street? Quite positively, it seems, as TipRanks analytics exhibit PHAS as a Strong Buy. Based on 5 analysts polled in the last 3 months, all 5 rate the stock a "buy." Meanwhile, the 12-month average price target stands at $18.33, marking nearly 340% upside from where the stock is currently trading. (See PhaseBio stock analysis on TipRanks)
- PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
52 Presentations by Coalition Members During the Annual Meeting WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- GlobeNewswire
Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association
DUBLIN, Ireland, Sept. 27, 2019 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative.
- GlobeNewswire
Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019
DUBLIN, Ireland, Sept. 26, 2019 -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative.
- GlobeNewswire
Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will provide a company overview and business update at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 1:50 p.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA™ (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
- Simply Wall St.
Is Nabriva Therapeutics (NASDAQ:NBRV) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- GlobeNewswire
Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the oral and intravenous (IV) formulations of XENLETA™ (lefamulin) are now available in the U.S. through major specialty distributors. XENLETA was approved by the U.S. Food and Drug Administration (FDA) on August 19, 2019 for the treatment of adults with community-acquired bacterial pneumonia (CABP). “The lack of innovative treatment options for CABP over the past two decades has resulted in increasing resistance in the most common bacteria causing CABP to multiple classes of antibiotics,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics.
- GlobeNewswire
Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Nabriva has earned a $5 million milestone payment under its licensing agreement with Sinovant Sciences related to the U.S. regulatory approval of XENLETA™ (lefamulin). Sinovant Sciences has an exclusive license to develop and commercialize lefamulin (SNV001) in the Greater China region. Sinovant Science’s application to conduct a clinical trial of lefamulin (SNV001) in China has been approved by China’s National Medical Products Administration, and the trial is expected to be initiated in the fourth quarter of 2019.
- GuruFocus.com
Nabriva Therapeutics Plc (NBRV) CEO Theodore R Schroeder Bought $89,500 of Shares
CEO of Nabriva Therapeutics Plc (30-Year Financial, Insider Trades) Theodore R Schroeder (insider trades) bought 50,000 shares of NBRV on 08/27/2019 at an average price of $1.79 a share. Continue reading...
- GlobeNewswire
Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Executive Officer Ted Schroeder will provide a company overview and business update at the 17th Annual Morgan Stanley Global Healthcare Conference on Monday, September 9, 2019 at 9:55 a.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XenletaTM (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. iBio (NYSE: IBIO ) shares were down 14% to ...
- Zacks
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
- Zacks
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
- Schaeffer's Investment Research
FDA Nods Fuel Unusual Options Volume on NBRV, MRNA
Call options are running much hotter than usual today
- Benzinga
Nabriva Analysts Bullish After FDA OKs Antibiotic; BofA Sees $200M Sales Potential
The FDA approved Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV )'s lead antibiotic asset, Xenleta, on Monday for the treatment of community-acquired bacterial infections. The Analysts Bank of America ...
- Benzinga
Nabriva Shares Rip Higher Following FDA Nod For Novel Antibiotic
Nabriava, a thinly-traded micro-cap biotech, announced late Monday the FDA approved its NDA for the oral and intravenous formulations of Xenleta, or lefamulin, for the treatment of community-acquired bacterial pneumonia, or CABP, in adults. Xenleta is the first IV and oral antibiotic with a novel mechanism of action, approved by the FDA in nearly two decades, the company said. Due to Xenleta novel mechanism of action, the likelihood of developing resistance as well as cross resistance with the beta-lactam, fluoroquinolone, glycopeptide, macrolide, and tetracycline antibiotic classes is low.
